The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

A record-breaking 4,432 scientific abstracts accepted at the American Heart Association’s meeting here adorned posters, ...

Clustered regularly interspaced palindromic repeats(CRISPR) gene editing, known for its precision, is revolutionizing tumor research and treatment. This article covers the evolution of the CRISPR ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes ...

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse ...

Ben Lamm, founder of Colossal Biosciences, aims to revive extinct species like the woolly mammoth using advanced genetic ...

The immune system faces a delicate balancing act: it must be aggressive enough to fight infections and cancer, yet restrained ...